The Emergence of a De Facto Fourth Hurdle for Pharmaceuticals in the United States
This article was originally published in SRA
Executive Summary
Joshua Cohen explains how the Medicare drug benefit will encourage health plans to evaluate drugs for cost as well as clinical effectiveness.